Corporate Communications
Week ending September 6, 2026
1. This week’s narrative in one paragraph
AI assistants are largely describing Ozempic in a neutral, explanatory way: the same active ingredient as Wegovy but different approved uses and dosing, with repeated emphasis on diabetes treatment, cardiovascular risk reduction, and safety precautions. The dominant story is “semaglutide products are related but not interchangeable by default,” although several answers say alternatives may have “no meaningful difference” if dose and formulation match. Safety content is prominent—hypoglycemia, pancreatitis, thyroid tumors, kidney monitoring, pregnancy, and contraindications—while competitive or favorable language is limited. The weight-loss association remains visible: answers repeatedly say Ozempic may be used off-label, while Wegovy is the approved weight-management product.
2. Anything with public-story potential
- Inconsistent answers about major safety warnings — prepare. For the labeling-comparison question, only two of seven responses mentioned the boxed warning and contraindications; thyroid-tumor and pancreatitis warnings were also inconsistently included. A public version of this story would be: “AI assistants give conflicting answers about what Ozempic’s major warnings are.”
- Conflicting answers about who should not take Ozempic — prepare/monitor. In the contraindications question, one of seven responses explicitly mentioned the boxed warning, while the others varied in whether they included hypoglycemia and kidney-related concerns. The public story would be: “People asking who should avoid Ozempic get different answers depending on the AI.”
- Substitution and compounded semaglutide — monitor. Three responses referenced compounding, and answers variably framed another semaglutide product as essentially equivalent. The likely story would be: “AI blurs the difference between Ozempic, other branded products, and compounded alternatives.”
3. Topics with a public-attention history
Compounding is quiet this week—three mentions versus 14 last week—but remains a sensitive access and authenticity topic. Off-label weight-loss use remains persistent at 15 mentions and continues to connect Ozempic with the broader weight-loss debate. Substitution/generic discussion is limited: only one biosimilar/generic tag and no pricing or access framing are visible. Safety concerns remain the most consistently recurring public-facing theme, particularly thyroid tumors, pancreatitis, pregnancy, and kidney injury.
4. Trajectory
This is a lower-volume week: 81 responses, 12 questions, and 22 inconsistency flags versus 120, 20, and 32 last week. Across the available period, safety themes are recurring rather than new. Overall inconsistency is down from recent highs, but contraindication, kidney, pregnancy, and allergy mentions rose modestly week over week despite lower volume. Competitor mentions also fell sharply, especially Wegovy (25 versus 44), Trulicity (7 versus 22), and Mounjaro (7 versus 23). No clear building narrative is evident.
5. Recommended actions
- Prepare a short holding statement on inconsistent AI safety answers, focused on directing people to current prescribing information and healthcare professionals; tied to the boxed-warning omissions across queries 125 and 119.
- Align with Medical Affairs, Regulatory, and PV on approved plain-language wording for thyroid-tumor, pancreatitis, pregnancy, and contraindication questions.
- Prepare concise talking points distinguishing Ozempic, Wegovy, and compounded semaglutide, given recurring off-label and substitution discussion.
- Monitor next week; no proactive media outreach. Current volume, inconsistency, compounding, and competitive mentions are all down.